Pfizer Czech Republic made a net profit of CZK 134 mil in 2014, down 7.25% when compared to the previous year. Historically, company's net profit reached an all time high of CZK 272 mil in 2008 and an all time low of CZK -29.9 mil in 2005.
This implies return on equity of 8.21% and return on invested capital of 16.1% in 2014. That is compared to 12.4% and 11.7% average seen in the last five years.
Since 2009, net profit of the firm increased by 70.4% or 11.2% a year on average.
As far as Pfizer Czech Republic's peers are concerned, Roche Czech Republic generated ROE of 8.00% and ROCE of 5.39% in 2014, Bayer Czech Republic's profitability reached 40.5% and 28.9%, respectively. Amgen Czech Republic operated with 21.7% and 45.1% returns in 2014..